Repligen Corporation

NASDAQ:RGEN

Medical - Instruments & Supplies

Healthcare
$172.67 -2.74%

-$3.66 today

Market cap
$11.04B
Beta
1.08
P/E (TTM)
142.4
EPS (TTM)
$0.91
52W Low $100.99High $175.77

Volume 1.30M

Average 1.08M

RGEN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Repligen CorporationNASDAQ: RGEN

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $14.42M rose 3.3% year over year, behind the +14.4% change in trailing-twelve-month research & development. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.

Context

  • Research & development amounted to 7.3% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.3% toward the trailing-twelve-month pace of +14.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$14.42M-0.3% QoQ
Last fiscal yearDec 2025
$54.18M+25.4% YoY
LTMJun 2026
$55.23M+14.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.3%——
1 year+25.4%——
3-year CAGR+7.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
54.18M USD
Year-over-year change
+25.4%
4-year CAGR
+12.1%

Research & Development vs competitors

How RGEN compares with its peers on the latest reported figures

  • RGEN's LTM Jun 2026 research & development of $55.23M is the 6th highest of the 9 companies compared; the peer median is $145.77M.
  • Its year-over-year change of +14.4% is the highest of 8, against a peer median of +5.5%.
  • Research & development amounts to 7.0% of revenue for RGEN, versus a peer median of 8.0%.
RGEN Competitors Peer median
Research & Development for RGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$1.41B -0.7%-1.7%3.0%
AAgilent Technologies, Inc.LTM Jul 2026$485M +8.5%-0.9%6.6%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M -14.3%+0.0%10.1%
QGENQiagen N.V.LTM Jun 2026$194.67M +5.5%-0.4%9.3%
TECHBio-Techne CorporationLTM Sep 2026$96.87M -3.0%+0.8%7.9%
RGENRepligen CorporationLTM Jun 2026$55.23M +14.4%+7.2%7.0%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$21.15M +13.2%+8.3%10.1%
BLFSBioLife Solutions, Inc.LTM Mar 2026$8.14M +5.5%-20.0%8.2%
AVTRAvantor, Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding RGEN) $145.77M+5.5%-0.4%8.0%

Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue670.53M801.54M632.36M634.44M738.26M
Cost of Revenue279.28M345.83M353.92M359.79M390.63M
Gross Profit391.25M455.71M278.44M274.65M347.62M
Gross Margin58.3%56.9%44.0%43.3%47.1%
Research & Development34.27M43.94M42.72M43.2M54.18M
Selling, General & Admin183.87M215.83M218.58M263.37M290.51M
Operating Expenses224.01M231.04M230.74M309.76M288.05M
Depreciation & Amortization38.45M57.01M86.11M86.56M96.96M
EBITDA203.27M277.31M145.32M80.26M182.51M
EBITDA Margin30.3%34.6%23.0%12.7%24.7%
Operating Income167.25M224.67M47.7M(35.11M)59.58M
Operating Margin24.9%28.0%7.5%-5.5%8.1%
Interest Income176K6.98M0027.57M
Interest Expense12.71M2.98M10.03M22.57M23.17M
Other Income / Expenses(13.71M)(5.53M)9M8.08M2.81M
Income Before Tax153.54M219.14M56.71M(27.04M)62.38M
Pre-Tax Margin22.9%27.3%9.0%-4.3%8.5%
Income Tax Expense25.25M33.18M21.11M(1.52M)13.49M
Net Income128.29M185.96M35.6M(25.51M)48.89M
Net Margin19.1%23.2%5.6%-4.0%6.6%
EPS (Basic)2.333.350.64(0.46)0.87
EPS (Diluted)2.243.240.63(0.46)0.86
Weighted Avg Shares55.02M55.46M55.72M55.94M56.23M
Weighted Avg Shares (Diluted)57.26M57.46M56.38M55.94M56.56M

Repligen Corporation

NASDAQ:RGEN

Intrinsic Alpha fair value

Locked

Current Price

$172.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.